Loading...
Loading...
OCGN| Name | Value |
|---|---|
| Revenues | 1.1M |
| Cost of Revenue | 8.9M |
| Gross Profit | -7.8M |
| Operating Expense | 16.6M |
| Operating I/L | -15.4M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.0M |
| Pretax | -15.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -15.3M |
Ocugen, Inc. is a clinical-stage biopharmaceutical company specializing in gene therapies for curing blindness diseases. Their pipeline includes OCU400, a gene therapy product candidate for inherited retinal diseases, OCU410 for dry age-related macular degeneration, and OCU200, a fusion protein in preclinical development for diabetic macular edema and retinopathy. The company generates revenue through strategic partnerships for gene therapy co-development and manufacturing, as well as commercialization agreements for their products in the United States market.
